Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $22.52
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
Daily · Wilder smoothing
| Oct 20, 26 |
| Jefferies |
| downgrade |
| Buy |
| Hold |
| Aug 6, 26 | UBS | maintain | Buy | Buy |
| Aug 6, 26 | Keybanc | maintain | Overweight | Overweight |
| Jul 22, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Jun 18, 26 | TD Cowen | maintain | Buy | Buy |
| May 7, 26 | JP Morgan | maintain | Overweight | Overweight |
| May 7, 26 | Citigroup | maintain | Buy | Buy |
| Feb 25, 26 | Keybanc | maintain | Overweight | Overweight |
| Feb 25, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 45.55 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 33.32 | Oscillator | Neutral |
| Williams %R (14) | -75.36 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.07 (Hist 0.04) | Oscillator | Buy |
| Average Directional Index (14) | 12.50 (+DI 18.2 / -DI 23.6) | Trend | Neutral |
| EMA 20 | 22.79 | MA | Sell |
| SMA 20 | 22.64 | MA | Sell |
| EMA 50 | 23.12 | MA | Sell |
| SMA 50 | 23.21 | MA | Sell |
| SMA 200 | 23.82 | MA | Strong Sell |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 20, 2026 | 2026-10-20 16:22:43 | View |
| 4 | Oct 20, 2026 | 2026-10-20 16:22:16 | View |
| 4 | Oct 20, 2026 | 2026-10-20 16:21:44 | View |
| 4 | Oct 19, 2026 | 2026-10-19 16:15:45 | View |
| 4 | Oct 6, 2026 | 2026-10-06 16:37:20 | View |
| 4 | Oct 6, 2026 | 2026-10-06 16:36:49 | View |
| 4 | Oct 6, 2026 | 2026-10-06 16:35:55 | View |
| 4 | Oct 1, 2026 | 2026-10-01 16:04:11 | View |
| 4 | Sep 22, 2026 | 2026-09-22 16:05:24 | View |
| 4 | Sep 22, 2026 | 2026-09-22 16:04:33 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ELAN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -54.9x | -29.4x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 19.8x | EPS est. 1.14 | Discount |
| Price / Book | 1.7x | 1.3x | Elevated |
| Price / Sales | 2.2x | 1.9x | Elevated |
| EV / EBITDA | 18.9x | 6.5x | Elevated |
| Return on equity | -3.0% | — | Weak |
| Gross margin | 52.6% | 43.7% | Above hist. |
| Debt / Equity | 0.59 | 0.78 | Moderate |
| Piotroski / Altman Z | 5/9 | Z 1.32 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 16, 26 | Modi Rajeev A. | officer: SEE REMARKS | A-Award | 63 | — |
| Oct 16, 26 | Simmons Jeffrey N | director, officer: PRESIDENT, CEO AND DIRECTOR | A-Award | 120 | — |
| Oct 16, 26 | Vanhimbergen Robert M | officer: EVP and CFO | A-Award | 8 | — |
| Oct 15, 26 | Bettington Timothy J | officer: SEE REMARKS | S-Sale | 4,350 @ $23.00 | $100.0K |
| Oct 2, 26 | Modi Rajeev A. | officer: SEE REMARKS | A-Award | 67 | — |
| Oct 2, 26 | Simmons Jeffrey N | director, officer: PRESIDENT, CEO AND DIRECTOR | A-Award | 128 | — |
| Oct 2, 26 | Vanhimbergen Robert M | officer: EVP and CFO | A-Award | 9 | — |
| Sep 30, 26 | Anand Kapila K | director | A-Award | 642 | — |
Stock news · updated daily
Preston brings more than two decades of global HR leadership and workforce innovation experience; Dave Kinard to retire at year-end INDIANAPOLIS, Oct. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Jamie Preston as Executive Vice President and Chief People Officer, effective November 3rd. Preston's appointment follows an extensive and competitive search as part of the company's commitment to attract, develop and retain an engaged global workforce while embedding inclusion, well-being and purpose into daily operations.
Apple just got cut, BlackRock got a lift, and chipmakers are under pressure ahead of a week packed with big-tech earnings. Find out which stocks Wall Street is moving on Tuesday and why the calls matter right now.
Elanco Animal Health Incorporated (NYSE: ELAN - Get Free Report) insider Timothy Bettington sold 4,350 shares of Elanco Animal Health stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total transaction of $100,050.00. Following the completion of the transaction, the insider directly owned 138,911 shares
Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Elanco Animal Health NYSE: ELAN President and CEO Jeff Simmons outlined the company's growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London.
State Street Corp grew its holdings in Elanco Animal Health Incorporated (NYSE: ELAN) by 4.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,063,046 shares of the company's stock after purchasing an additional 726,567 shares during the quarter. State Street Corp owned
Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Elanco Animal Health (NYSE: ELAN - Get Free Report) and Amarin (NASDAQ: AMRN - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Volatility and Risk Elanco Animal Health has a
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | 0.27 | 0.34 | Beat 26.3% | $1.37B |
| May 6, 2026 | 0.35 | 0.40 | Beat 15.7% | $1.37B |
| Feb 24, 2026 | 0.11 | 0.13 | Beat 18.2% | $1.14B |
| Nov 5, 2025 | 0.13 | 0.19 | Beat 46.2% | $1.14B |
| Aug 7, 2025 | 0.20 | 0.26 | Beat 30.0% | $1.24B |
| May 7, 2025 | 0.31 | 0.37 | Beat 19.4% | $1.19B |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure